RxDoctor Payments Data

Samuel Bennett

Family · Watkinsville, GANPI 1255192944

Payments from drug & device makers

$5,570in general payments, 2019–2025

Across 281 payments — averaging $19.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$988
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$784
  • Johnson & Johnson$464
  • Takeda Pharmaceuticals U.S.A., Inc.$459
  • Regeneron Healthcare Solutions, Inc.$426
  • Sanofi$371
  • plus $2K from 20 others

What the payments were for

  • Food & beverage$5,37196%
  • Education$1994%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,570 in reported general payments places this provider in the 90th percentile of 6,258 family providers in Georgia.

See all family providers in Georgia

Medicare billing

Part B allowed, 2024
$29,562
Medicare patients
224
Services billed
324

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LinzessLinaclotide32$31,452
VoqueznaVonoprazan Fumarate15$9,587
ClenpiqSod Picosulf/Mag Ox/Citric Ac49$8,365
PlenvuPeg3350/Sod Sul/Nacl/Kcl/Asb/C38$5,447
Colesevelam Hcl62$3,593
Sucralfate55$2,231
Mesalamine ErMesalamine12$1,510
Pantoprazole Sodium116$1,343
Ondansetron OdtOndansetron55$779
Omeprazole42$452
Gavilyte-CPeg3350/Sod Sulf,bicarb,cl/Kcl26$432
Dicyclomine Hcl36$403
Metoclopramide Hcl71$266
Azithromycin18$184
Famotidine25$175

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess$988$31,45232 claims
Phathom Pharmaceuticals, Inc.Voquezna$226$9,58715 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCPlenvu$784$5,44738 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 6,258 family providers in Georgia.

Other family in Watkinsville

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →